178 related articles for article (PubMed ID: 38364506)
1. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
[TBL] [Abstract][Full Text] [Related]
2. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
3. Generation of gene corrected human isogenic iPSC lines (IDVi003-A_CR13, IDVi003-A_CR21, IDVi003-A_CR24) from an inherited retinal dystrophy patient-derived IPSC line ITM2B-5286-3 (IDVi003-A) carrying the ITM2B c.782A > C variant using CRISPR/Cas9.
Ben Yacoub T; Letellier C; Wohlschlegel J; Condroyer C; Slembrouck-Brec A; Goureau O; Zeitz C; Audo I
Stem Cell Res; 2023 Sep; 71():103166. PubMed ID: 37473460
[TBL] [Abstract][Full Text] [Related]
4. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
[TBL] [Abstract][Full Text] [Related]
5. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
[TBL] [Abstract][Full Text] [Related]
6. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
[TBL] [Abstract][Full Text] [Related]
7. Generation of a ST3GAL3 null mutant induced pluripotent stem cell (iPSC) line (UKWMPi002-A-3) by CRISPR/Cas9 genome editing.
Diouf D; Vitale MR; Zöller JEM; Pineau AM; Klopocki E; Hamann C; Ziegler GC; Vanmierlo T; Van den Hove D; Lesch KP
Stem Cell Res; 2023 Mar; 67():103038. PubMed ID: 36746102
[TBL] [Abstract][Full Text] [Related]
8. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
Lilianty J; Bateman JF; Lamandé SR
Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
[TBL] [Abstract][Full Text] [Related]
9. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
[TBL] [Abstract][Full Text] [Related]
10. Generation of a heterozygous TPM1-E192K knock-in human induced pluripotent stem cell line using CRISPR/Cas9 system.
Kang JY; Mun D; Chun Y; Kim H; Yun N; Lee SH; Joung B
Stem Cell Res; 2022 Aug; 63():102878. PubMed ID: 35917600
[TBL] [Abstract][Full Text] [Related]
11. Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology.
Fulgencio-Covián A; Álvarez M; Pepers BA; López-Márquez A; Ugarte M; Pérez B; van Roon-Mom WMC; Desviat LR; Richard E
Stem Cell Res; 2020 Dec; 49():102055. PubMed ID: 33128956
[TBL] [Abstract][Full Text] [Related]
12. Modeling of dilated cardiomyopathy by establishment of isogenic human iPSC lines carrying phospholamban C25T (R9C) mutation (UPITTi002-A-1) using CRISPR/Cas9 editing.
Barndt RJ; Ma N; Tang Y; Haugh MP; Alamri LS; Chan SY; Wu H
Stem Cell Res; 2021 Oct; 56():102544. PubMed ID: 34583280
[TBL] [Abstract][Full Text] [Related]
13. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
[TBL] [Abstract][Full Text] [Related]
14. Generation of a pluripotent stem cell line (UMGi270-A) and a corresponding CRISPR/Cas9 modified isogenic control (UMGi270-A-1) from a patient with sudden onset dilated cardiomyopathy harboring a FLNC p.R2187P mutation.
Maurer W; Rebs S; Köhne S; Eberl H; Wollnik B; Zibat A; Streckfuss-Bömeke K
Stem Cell Res; 2024 Jun; 77():103409. PubMed ID: 38583294
[TBL] [Abstract][Full Text] [Related]
15. Generation of a gene corrected human isogenic iPSC line (CPGHi001-A-1) from a hearing loss patient with the TMC1 p.M418K mutation using CRISPR/Cas9.
Wang H; Luo Y; Li J; Guan J; Yang S; Wang Q
Stem Cell Res; 2022 Apr; 60():102736. PubMed ID: 35247837
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 gene editing of a SOX9 reporter human iPSC line to produce two TRPV4 patient heterozygous missense mutant iPSC lines, MCRIi001-A-3 (TRPV4 p.F273L) and MCRIi001-A-4 (TRPV4 p.P799L).
Nur Patria Y; Stenta T; Lilianty J; Rowley L; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
Stem Cell Res; 2020 Oct; 48():101942. PubMed ID: 32771907
[TBL] [Abstract][Full Text] [Related]
17. Generation of a human induced pluripotent stem cell line JHUi004-A with heterozygous mutation for spinocerebellar ataxia type 12 using genome editing.
Liu HB; Dong T; Deng L; Zhou C; Tang F; Margolis RL; Li PP
Stem Cell Res; 2024 Jun; 77():103441. PubMed ID: 38759410
[TBL] [Abstract][Full Text] [Related]
18. Using CRISPR/Cas9 to generate a heterozygous COL2A1 p.R719C iPSC line (MCRIi019-A-6) model of human precocious osteoarthritis.
Yammine KM; Mirda Abularach S; Sampurno L; Bateman JF; Lamandé SR; Shoulders MD
Stem Cell Res; 2023 Mar; 67():103020. PubMed ID: 36682125
[TBL] [Abstract][Full Text] [Related]
19. Generation of a gene-corrected isogenic iPSC line (AHQUi001-A-1) from a patient with familial hypertriglyceridemia (FHTG) carrying a heterozygous p.C310R (c.928 T > C) mutation in LPL gene using CRISPR/Cas9.
Sun X; Zhou X; Dong B; Wang C; Xiao X; Wang Y
Stem Cell Res; 2021 Apr; 52():102230. PubMed ID: 33592566
[TBL] [Abstract][Full Text] [Related]
20. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
Thamodaran V; Rani S; Velayudhan SR
Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
